Incyte Corporation (NASDAQ:INCY) is set to announce its earnings results before the market opens on Tuesday, October 31st. Analysts expect the company to announce earnings of $0.05 per share for the quarter.

Incyte Corporation (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.01). Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The firm had revenue of $326.40 million for the quarter, compared to the consensus estimate of $318.45 million. During the same quarter last year, the company earned $0.18 earnings per share. The firm’s revenue was up 32.5% on a year-over-year basis. On average, analysts expect Incyte Corporation to post $-0.82 EPS for the current fiscal year and $0.31 EPS for the next fiscal year.

Incyte Corporation (INCY) traded up 0.72% during midday trading on Tuesday, reaching $114.30. 955,878 shares of the company’s stock were exchanged. The company’s market cap is $23.51 billion. Incyte Corporation has a 52 week low of $83.01 and a 52 week high of $153.15. The firm has a 50-day moving average price of $117.36 and a 200 day moving average price of $125.07.

ILLEGAL ACTIVITY WARNING: “Incyte Corporation (INCY) to Release Quarterly Earnings on Tuesday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/24/incyte-corporation-incy-to-release-quarterly-earnings-on-tuesday.html.

In other news, President Herve Hoppenot sold 70,502 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $119.45, for a total value of $8,421,463.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Eric H. Siegel sold 1,820 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $132.92, for a total transaction of $241,914.40. Following the completion of the transaction, the executive vice president now owns 23,553 shares of the company’s stock, valued at $3,130,664.76. The disclosure for this sale can be found here. Insiders sold a total of 102,967 shares of company stock valued at $12,857,016 over the last 90 days. Corporate insiders own 17.70% of the company’s stock.

Several analysts recently commented on INCY shares. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating and set a $135.00 target price on shares of Incyte Corporation in a report on Thursday, August 31st. BMO Capital Markets reaffirmed a “buy” rating and set a $172.00 target price on shares of Incyte Corporation in a report on Friday, July 21st. Barclays PLC reaffirmed an “overweight” rating and set a $165.00 target price (down previously from $180.00) on shares of Incyte Corporation in a report on Wednesday, August 2nd. Royal Bank Of Canada started coverage on shares of Incyte Corporation in a report on Thursday, September 14th. They set a “sector perform” rating and a $136.00 target price for the company. Finally, Raymond James Financial, Inc. raised shares of Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 target price for the company in a report on Monday, September 11th. Seven research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Incyte Corporation presently has an average rating of “Buy” and an average price target of $144.84.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Earnings History for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.